logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

R/M HNSCC: durvalumab shows benefit in PD-L1-low/negative disease

CONDOR phase 2 data for durvalumab with/without tremelimumab.